Recorded fact · drug.label_indication
drug.label_indication for tirzepatide|type-2-diabetes
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 1a20741f resolves to.
The record
| Fact id | 1a20741f384d455d779bd009 |
|---|---|
| Entity | drug: tirzepatide|type-2-diabetes |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260729 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 39719e4a9266dc25f42d9c51fe6d423192eaf1e3d800bb3dac736db298c531cf.
The value
{
"ingredient": "Tirzepatide",
"conditionId": "type-2-diabetes",
"conditionName": "Type 2 diabetes",
"matchedAlias": "type 2 diabetes",
"context": "indication",
"brand": "MOUNJARO",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "0818426a-53eb-4db7-9609-bbae1e7a3964",
"labelEffectiveTime": "20260729",
"labelsRead": 8,
"labelsNaming": 7,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 590b90999709b8b20ca72f78d41a3c0519865b0ba3d0218051079515928c674a.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.